[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
[HTML][HTML] Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
…, DC Mastellos, S Metallidis… - The Journal of …, 2020 - Am Soc Clin Investig
Emerging data indicate that complement and neutrophils contribute to the maladaptive
immune response that fuels hyperinflammation and thrombotic microangiopathy, thereby …
immune response that fuels hyperinflammation and thrombotic microangiopathy, thereby …
Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the …
…, SG Giotaki, P Gargalianos, S Metallidis… - JAMA network …, 2020 - jamanetwork.com
Importance Severe acute respiratory syndrome coronavirus 2 infection has evolved into a
global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable …
global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable …
[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
…, P Panagopoulos, V Petrakis, S Metallidis… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
…, D Canario, E Fernández-Cruz, S Metallidis… - The Lancet, 2022 - thelancet.com
Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG)
to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific …
to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific …
[PDF][PDF] Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms,
but many develop severe symptoms associated with an excessive inflammatory response. …
but many develop severe symptoms associated with an excessive inflammatory response. …
[HTML][HTML] Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece
…, M Gavana, A Vantarakis, M Psichogiou, S Metallidis… - PLoS …, 2020 - journals.plos.org
Background Although combined antiretroviral therapy has substantially improved the
prognosis of people living with HIV (PLHIV), mortality remains higher compared to the general …
prognosis of people living with HIV (PLHIV), mortality remains higher compared to the general …
Microbiological characteristics of bacteremias among COVID-19 hospitalized patients in a tertiary referral hospital in Northern Greece during the second epidemic …
…, I Gkeka, M Archonti, S Kati, S Metallidis… - FEMS …, 2021 - academic.oup.com
Northern Greece was struck by an intense second COVID-19 (coronavirus disease 2019)
epidemic wave during the fall of 2020. Because of the coinciding silent epidemic of multidrug-…
epidemic wave during the fall of 2020. Because of the coinciding silent epidemic of multidrug-…
[HTML][HTML] Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the …
…, A Kotsaki, IM Gounaridi, E Christaki, S Metallidis… - …, 2023 - thelancet.com
Background The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …